` EYE (Nova Eye Medical Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

EYE
vs
S
S&P/ASX 300

Over the past 12 months, EYE has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
EYE vs S&P/ASX 300

Loading
EYE
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
EYE vs S&P/ASX 300

Loading
EYE
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
EYE vs S&P/ASX 300

Loading
EYE
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Nova Eye Medical Ltd vs Peers

S&P/ASX 300
EYE
ABT
ISRG
BSX
SYK
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Nova Eye Medical Ltd
Glance View

Market Cap
39.8m AUD
Industry
Health Care

Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia and currently employs 130 full-time employees. The firm is focused on developing, manufacturing and selling a portfolio of ophthalmic treatment technologies and devices. Its technologies include iTrack minimally invasive glaucoma surgery (MIGS), which is a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patients' reliance on anti-glaucoma medications for mild-moderate glaucoma. Its Molteno3 glaucoma drainage device platform is designed to manage surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma. The firm's 2RT is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD).

EYE Intrinsic Value
0.28 AUD
Undervaluation 49%
Intrinsic Value
Price
Back to Top